Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes

Alireza Esteghamati, Mehrnaz Ghasemiesfe, Mostafa Mousavizadeh, Sina Noshad, Manouchehr Nakhjavani, Alireza Esteghamati, Mehrnaz Ghasemiesfe, Mostafa Mousavizadeh, Sina Noshad, Manouchehr Nakhjavani

Abstract

Aims/introduction: Chemerin, a novel member of the family of adipocytokines, has been shown to be associated with insulin resistance, as well as micro- and macrovascular complications of diabetes. We investigated the effects of pioglitazone and metformin, two commonly prescribed antidiabetic agents, on the reduction of serum chemerin concentrations.

Materials and methods: In an open-labeled randomized clinical trial, 81 patients with newly diagnosed type 2 diabetes who were not taking antidiabetic medications were recruited. Patients were randomly assigned to either pioglitazone 30 mg daily or metformin 1,000 mg daily. Serum chemerin concentrations, indices of glycemic control, serum lipids concentrations, and anthropometric parameters were measured at baseline and after 3 months.

Results: Pioglitazone and metformin did not alter waist circumference, weight or body mass index after 3 months. In contrast, all indices of glycemia and insulin resistance improved substantially after 3 months' treatment with both medications (P < 0.01 in all analyses). There was a significant decrease in chemerin concentrations after 3 months in the pioglitazone group (P = 0.008). Similarly, metformin caused a significant drop in chemerin concentrations at week 12 (P = 0.015). When compared, metformin and pioglitazone proved to be equally effective in the alleviation of chemerin concentrations (P = 0.895, effect size: 0.1%).

Conclusions: The present findings show that pioglitazone and metformin have comparable efficacy on serum chemerin concentrations, albeit through different mechanisms. Future studies need to focus on the clinical implications of lowered chemerin concentration on improvement of diabetes complications. This trial was registered with ClinicalTrials.gov (no. NCT01593371).

Keywords: Chemerin; Metformin; Pioglitazone.

References

    1. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006; 14(Suppl. 5): 242S–249S
    1. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548–2556
    1. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S64–S73
    1. Zabel BA, Allen SJ, Kulig P, et al Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005; 280: 34661–34666
    1. Bozaoglu K, Bolton K, McMillan J, et al Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687–4694
    1. Verrijn Stuart AA, Schipper HS, Tasdelen I, et al Altered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetes. J Clin Endocrinol Metab 2012; 97: 463–472
    1. El‐Mesallamy HO, El‐Derany MO, Hamdy NM. Serum omentin‐1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med 2011; 28: 1194–1200
    1. Hu W, Yu Q, Zhang J, et al Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in the kidney of streptozotocin‐induced diabetic rats. Inflammation 2012; 35: 1287–1293
    1. Lin X, Tang X, Jiang Q, et al Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab 2012; 58: 539–544
    1. Yoo HJ, Choi HY, Yang SJ, et al Circulating chemerin level is independently correlated with arterial stiffness. J Atheroscler Thromb 2012; 19: 59–66
    1. Vernochet C, Peres SB, Davis KE, et al C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator‐activated receptor gamma agonists. Mol Cell Biol 2009; 29: 4714–4728
    1. Tan BK, Chen J, Farhatullah S, et al Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009; 58: 1971–1977
    1. Pei L, Yang J, Du J, et al Downregulation of chemerin and alleviation of endoplasmic reticulum stress by metformin in adipose tissue of rats. Diabetes Res Clin Pract 2012; 97: 267–275
    1. American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care 2011; 34(Suppl. 1): S62–S69
    1. Matthews DR, Hosker JP, Rudenski AS, et al Homeostasis model assessment: insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419
    1. Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev 2011; 22: 331–338
    1. Sell H, Laurencikiene J, Taube A, et al Chemerin is a novel adipocyte‐derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009; 58: 2731–2740
    1. Roh S, Song SH, Choi KC, et al Chemerin–a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007; 362: 1013–1018
    1. Wittamer V, Franssen JD, Vulcano M, et al Specific recruitment of antigen‐presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977.
    1. Bozaoglu K, Segal D, Shields KA, et al Chemerin is associated with metabolic syndrome phenotypes in a Mexican‐American population. J Clin Endocrinol Metab 2009; 94: 3085–3088
    1. Lehmann JM, Moore LB, Smith‐Oliver TA, et al An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator‐activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953–12956
    1. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab 2006; 4: 263–273
    1. Hofmann C, Lorenz K, Colca JR. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 1991; 129: 1915–1925
    1. Fukui Y, Masui S, Osada S, et al A new thiazolidinedione, NC‐2100, which is a weak PPAR‐gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 2000; 49: 759–767
    1. Wilson‐Fritch L, Burkart A, Bell G, et al Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 2003; 23: 1085–1094
    1. Ozcan U, Cao Q, Yilmaz E, et al Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457–461
    1. Ozcan U, Yilmaz E, Ozcan L, et al Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137–1140
    1. Kralisch S, Weise S, Sommer G, et al Interleukin‐1fl induces the novel adipokine chemerin in adipocytes in vitro. Regul Pept 2009; 154: 102–106
    1. Kloting N, Fasshauer M, Dietrich A, et al Insulin‐sensitive obesity. Am J Physiol Endocrinol Metab 2010; 299: E506–E515

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever